Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    alemtuzumab | Interventional Studies | multiple sclerosis | Phase 3
Show Display Options
Rank Status Study
1 Completed An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: alemtuzumab
2 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab;   Biological: Interferon beta-1a
3 Completed
Has Results
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Alemtuzumab 12 mg;   Biological: Alemtuzumab 24 mg;   Biological: Interferon beta-1a
4 Unknown  Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Drug: Alemtuzumab
5 Active, not recruiting Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: MabCampath-1h

Study has passed its completion date and status has not been verified in more than two years.